Raffa R B, Connelly C D
CNS Research, R.W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477-0776.
NIDA Res Monogr. 1990;105:391-2.
Considerable data support the hypothesis that mammalian FMRFamide (Phe-Met-Arg-Phe-NH2) or mammalian FMRFamide-related peptides (FaRPs) function as endogenous antiopiates (for review see Raffa, 1988). We report here that central administration (i.c.v.) of a FaRP with D-amino acid substitution in the second position, i.e. [D-Met2]-FMRFamide (DMFa), produces dose-related, naloxone-reversible antinociception in the mouse tail-flick test. Hence, this modification appears to confer agonist-like activity.